| Stereochemistry | ABSOLUTE |
| Molecular Formula | C16H21Cl2NO |
| Molecular Weight | 314.25 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 4 / 4 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
COC[C@H]1[C@H]2CC[C@@H](C[C@@H]1C3=CC=C(Cl)C(Cl)=C3)N2C
InChI
InChIKey=PGYDXVBZYKQYCS-VPWBDBDCSA-N
InChI=1S/C16H21Cl2NO/c1-19-11-4-6-16(19)13(9-20-2)12(8-11)10-3-5-14(17)15(18)7-10/h3,5,7,11-13,16H,4,6,8-9H2,1-2H3/t11-,12+,13+,16+/m0/s1
NS-2359, an orally active, triple monoamine reuptake inhibitor that inhibits the reuptake of dopamine, noradrenaline and serotonin, is being developed by Saniona and the Treatment Research Center (TRC) at the University of Pennsylvania for the treatment of Cocaine abuse. NS-2359’s pharmacological profile means that it may be able to reduce cocaine withdrawal symptoms, reduce cocaine craving and reduce cocaine-induced euphoria. Previously NS-2359 was in clinical trials for the treatment of attention-deficit hyperactivity disorder and major depressive disorder, but development was discontinued due to lack of effectiveness.
CNS Activity
Originator
Approval Year
PubMed
Sample Use Guides
Cocaine Use Disorder: the initial dose of the NS-2359 will be two mg once daily. Patients with difficult adverse events at the 2 mg dose will be allowed to reduce to 1 mg once daily. Subjects will participate in weekly cognitive behavioral relapse prevention psychotherapy from week 2 through week 9.
Route of Administration:
Oral
ACTIVE MOIETY
